MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/90/0.1/20.12.24 Stock

Warrant

DE000ME224B5

Market Closed - Börse Stuttgart 15:20:14 2024-07-05 EDT
0.063 EUR +14.55% Intraday chart for MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/90/0.1/20.12.24
Current month-4.55%
1 month-8.70%
Date Price Change
24-07-05 0.063 +14.55%
24-07-04 0.055 -22.54%
24-07-03 0.071 +9.23%
24-07-02 0.065 +4.84%
24-07-01 0.062 -6.06%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 03:20 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME224B
ISINDE000ME224B5
Date issued 2023-10-13
Strike 90 $
Maturity 2024-12-20 (168 Days)
Parity 10 : 1
Emission price 0.92
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1
Lowest since issue 0.05
Delta-0.04x
Omega 7.561
Premium37.29x
Gearing198.99x
Moneyness 0.6322
Difference Strike -52.37 $
Difference Strike %-58.19%
Spread 0.006
Spread %8.70%
Theoretical value 0.0660
Implied Volatility 43.21 %
Total Loss Probability 93.15 %
Intrinsic value 0.000000
Present value 0.0660
Break even 89.28 €
Theta-0.01x
Vega0.01x
Rho-0x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus